IMNM
Immunome, Inc.
There isn't enough reported data to score IMNM yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
IMNM Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
IMNM's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
IMNM PE Valuation
IMNM has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
IMNM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect IMNM's losses to grow, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
IMNM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.65 | +$0.13 |
| Q2 2026 | -$2.54 | +$0.37 |
| Q1 2026 | -$2.39 | +$0.62 |
| Q4 2025 | -$2.43 | +$2.57 |
| Q3 2025 | -$2.78 | +$5.32 |
| Q2 2025 | -$2.91 | +$4.77 |
| Q1 2025 | -$3.01 | +$4.53 |
| Q4 2024 | -$5.00 | +$0.38 |
IMNM is still losing money, but far less than before: $2.65 per share over the past year, against $8.10 at its worst in late 2024.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over IMNM on earnings quality, reporting a profit while its opponent remains loss making.
IMNM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $4M | +70% |
| Q1 2025 | $2.9M | +184% |
| Q4 2024 | $2.7M | -28% |
| Q3 2024 | $2.9M | -18% |
| Q2 2024 | $2.4M | -45% |
| Q1 2024 | $1M | -56% |
IMNM's revenue has slid since its 2023 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -1158% | +535 points |
| Q1 2025 | -1526% | +11332 points |
| Q4 2024 | -3030% | -556 points |
| Q3 2024 | -1736% | -1606 points |
| Q2 2024 | -1692% | -1557 points |
| Q1 2024 | -12857% | -12668 points |
| Q4 2023 | -2474% | N/A |
| Q3 2023 | -130% | N/A |
IMNM's operating margin was −1158% last quarter, up 535 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over IMNM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
IMNM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$61.2M | -$19.6M |
| Q2 2026 | -$63.9M | -$13.6M |
| Q1 2026 | -$61.6M | -$4.9M |
| Q4 2025 | -$52M | -$8.8M |
| Q3 2025 | -$41.6M | -$5.9M |
| Q2 2025 | -$50.3M | -$24.6M |
| Q1 2025 | -$56.7M | -$43.4M |
| Q4 2024 | -$43.2M | -$25.4M |
IMNM has burned cash in almost every quarter: −$239M over the past year, against −$192M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over IMNM on cash generation, producing positive trailing cash flow while its opponent burns cash.
IMNM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +292K shares |
| 1 year | +31% | +26.6M shares |
| 3 years | +836% | +101M shares |
| 5 years | +10090% | +112M shares |
IMNM has 114M diluted shares, up 31% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over IMNM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
IMNM Net Leverage
IMNM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
IMNM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.7 | Neutral |
| Stochastic | 15.6 | Oversold |
IMNM's weekly RSI is 42 (neutral) and its Stochastic is 16 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
IMNM PE vs Healthcare Sector
IMNM has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
IMNM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.0 | 1.5% below |
| 20 week MA | $22.5 | 17% below |
| 50 week MA | $21.9 | 15% below |
| 100 week MA | $16.2 | 15% above |
| 200 week MA | $13.7 | 36% above |
IMNM has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 36% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over IMNM on trend strength, trading above more of its moving averages.
IMNM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.5 | $10.2 | -24% |
| 2021 | $10.2 | $16.5 | +62% |
| 2022 | $16.5 | $3.15 | -81% |
| 2023 | $3.15 | $10.7 | +240% |
| 2024 | $10.7 | $10.5 | -1.5% |
| 2025 | $10.5 | $21.7 | +106% |
| 2026 YTD | $21.7 | $18.7 | -14% |
IMNM's yearly returns have swung widely, from +240% in 2023 to −81% in 2022. It's down 14% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over IMNM on returns for 2026, with the stronger performance.